• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ultragenyx Pharmaceutical Inc.

    2/12/25 11:42:47 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RARE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Ultragenyx Pharmaceutical Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    90400D108

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    90400D108


    1Names of Reporting Persons

    SANDS CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,965,104.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,298,003.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,298,003.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    90400D108


    1Names of Reporting Persons

    SANDS FRANK M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,965,104.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,298,003.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,298,003.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ultragenyx Pharmaceutical Inc.
    (b)Address of issuer's principal executive offices:

    60 LEVERONI COURT, 60 LEVERONI COURT, NOVATO, CALIFORNIA, 94949.
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed jointly by Sands Capital Management, LLC ("SCM") and Frank M. Sands ("Sands"). Sands holds ultimate voting and investment power over securities held by SCM.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of SCM and Sands is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.
    (c)Citizenship:

    Sands Capital Management, LLC is organized under the laws of the State of Delaware. Sands is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    90400D108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See rows 5 through 11 of cover pages.
    (b)Percent of class:

    See rows 5 through 11 of cover pages.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See rows 5 through 11 of cover pages.

     (ii) Shared power to vote or to direct the vote:

    See rows 5 through 11 of cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    See rows 5 through 11 of cover pages.

     (iv) Shared power to dispose or to direct the disposition of:

    See rows 5 through 11 of cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Securities reported on this Schedule 13G are held in the accounts of various clients of Sands Capital Management, LLC, which may include pension plans, endowments, foundations, mutual funds, charities, state and municipal government entities, Taft-Hartley plans, families, and individuals, among other types. Such clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No such client's interest in the class of securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SCM is reporting hereunder as an investment adviser pursuant to Item 3(e) above. Sands is reporting hereunder as a control person pursuant to Item 3(g) above.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SANDS CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Alexandra R. Fulk
    Name/Title:Alexandra R. Fulk, Chief Compliance Officer, Senior Counsel
    Date:02/12/2025
     
    SANDS FRANK M.
     
    Signature:/s/ Frank M. Sands
    Name/Title:Frank M. Sands
    Date:02/12/2025
    Get the next $RARE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RARE

    DatePrice TargetRatingAnalyst
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    4/22/2024$77.00Outperform
    RBC Capital Mkts
    12/8/2023$72.00Overweight
    Wells Fargo
    6/14/2023$96.00Outperform
    Credit Suisse
    6/6/2023$60.00 → $80.00In-line → Outperform
    Evercore ISI
    4/26/2023$114.00Overweight
    Cantor Fitzgerald
    1/18/2023$90.00Buy
    Canaccord Genuity
    12/30/2022$82.00Buy
    H.C. Wainwright
    More analyst ratings

    $RARE
    SEC Filings

    See more
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      5/6/25 4:10:49 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.

      DEFA14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:01:02 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ultragenyx Pharmaceutical Inc.

      DEF 14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:00:35 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Financials

    Live finance-specific insights

    See more
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

      2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. "We have created a ne

      2/13/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/5/25 7:18:48 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/10/25 12:53:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:19:57 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      11/14/24 6:42:29 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 10:03:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 7:46:34 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

      NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed t

      5/7/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ultragenyx Pharma upgraded by Goldman with a new price target

      Goldman upgraded Ultragenyx Pharma from Neutral to Buy and set a new price target of $67.00 from $56.00 previously

      6/6/24 7:19:22 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ultragenyx Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ultragenyx Pharma with a rating of Outperform and set a new price target of $77.00

      4/22/24 7:43:41 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

      Wells Fargo initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $72.00

      12/8/23 7:56:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

      NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,

      7/12/23 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

      NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx's chief medical officer for gene therapy and inborn errors of metabolism. "Eric has extensive expertise in the development and execution of clinical development programs for rare genetic disorders and has been a driving force for our entire gene therapy pipeline," said Emil D. Kakkis, M.D., Ph.D., chief executive of

      3/14/23 8:30:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

      NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. "Dr. Ray brings to our Board of Directors decades of global experience as a physician researcher, biopharmaceutical executive, and champion for patient access to innovative treatments," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "His expertise

      4/22/22 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care